secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000875320-24-000142
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Pharmaceuticals Shareholders Elect Directors and Approve Proposals at Annual Meeting
--------------------------------------------------------------------------------

- Shareholders elected all 11 board nominees, including Reshma Kewalramani and Jeffrey Leiden, with each receiving over 217 million votes for.
- Ratification of Ernst & Young as independent auditor for FY2024 approved with 229,460,523 votes for, 3,987,619 against.
- Advisory vote on 2023 executive compensation program passed with 202,098,575 votes for, 19,223,784 against.
- Shareholder proposal for special shareholder meeting improvement approved with 160,438,357 votes for, 61,494,550 against.
- Shareholder proposal on racial and gender pay gaps report did not pass, receiving only 63,865,687 for vs 157,637,997 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000142/0000875320-24-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000142/vrtx-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer